Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.

Abstract

The role of prostate specific antigen (PSA) nadir in the definition of disease freedom after radiotherapy of prostate cancer is controversial. We evaluate post-irradiation PSA nadir in men apparently cured of this disease. From 1984 to 1993, 354 men with clinical stage T1T2N0 prostate cancer were treated with radioactive 125iodine prostate implant followed by external beam radiation. Median pretreatment PSA was 8.4 ng/ml (range 0.3 to 188). Of these men 250 are disease-free and median pretreatment PSA was 6.5 ng/ml (range 0.3 to 123). Treatment failure is defined as 3 consecutive PSA increases above nadir. Median followup is 7 years (range 5 to 14 years) for the 250 disease-free men and 6 years (range 0.5 to 14) for all 354 men. PSA nadir 0.5 ng/ml or less was achieved by 98% of all disease-free men (244 of 250) with minimum 5-year followup, including 87% (217) who achieved nadir 0.2 ng/ml or less. All 27 disease-free men with minimum 10-year followup had a PSA nadir of 0.5 ng/ml or less. PSA nadir significantly correlated with disease-free survival by receiver operator characteristics curve analysis (0.93 area under the curve) in all 354 men. PSA nadir is the fundamental measurement that determines possible cure after radiotherapy. Except for perhaps rare occasions, men must at least achieve a nadir of 0.5 ng/ml. or less to be cured of prostate cancer by irradiation. However, the prognostic value of this nadir level depends on most men achieving a nadir of 0.2 ng/ml or less. Disease freedom for radiotherapy, defined as achievement and maintenance of PSA nadir 0.5 ng/ml or less, is reasonable.